Abstract
A survey of members of the Japan Society of Gynecologic Oncology revealed that 93% of the members use the present Guideline for Ovarian Cancer Treatment in practice. There is an international consensus about first-line treatment for ovarian cancer. In contrast, the treatment for sex-cord stromal tumor, which is rare, and recurrent cancer are not standardized. In addition, management for borderline malignant tumor has been controversial. The new revision incorporates a new chapter regarding these matters. The revised Guideline may be more useful. We hope that re-examination and future revisions will be made to continually update the Guideline.
| Original language | English |
|---|---|
| Pages (from-to) | 617-619 |
| Number of pages | 3 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 37 |
| Issue number | 4 |
| Publication status | Published - 2010 Apr 6 |
Keywords
- Guideline
- Ovarian cancer
- Treatment
ASJC Scopus subject areas
- Oncology
- Cancer Research
